StockpollyBeta
Get App
Delisting riskPopularity #3,534
BIAF · NASDAQ · Medical - Diagnostics & Research

bioAffinity Technologies (BIAF)

Runs a pathology laboratory and sells a sputum-based lung-cancer assessment test.

$8.50
After hours−0.09 (−1.05%)
At close$8.59(+11.56%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue022222211212
Cost of revenue022112111115
Gross profit00111000000−3
333333333340
Research & development010001100100
222223222333
General & administrative000000000003
Other expenses00000000000−3
Operating income−2−2−2−2−2−3−3−3−2−3−4−3
0000000−2−3000
Interest income000000000000
Interest expense000000000000
Other non-operating income00000—023000
Income before tax−2−2−2−2−2−3−3−4−5−3−4−3
Income tax expense000000000000
Net income from continuing operations−2−2−2−2−2−3−3−4−5−3−4−3
Net income−2−2−2−2−2−3−3−4−5−3−4−3
EPS, basic−$7.80−$117.00−$90.00−$85.50−$72.00−$94.50−$72.00−$76.05−$71.10−$27.30−$12.15−$9.60
EPS, diluted−$7.80−$117.00−$90.00−$85.50−$72.00−$90.00−$72.00−$76.05−$71.10−$27.30−$12.15−$9.60
Weighted average shares, basic000000000000
Weighted average shares, diluted000000000000
EBITDA−2−2−2−2−2−3−2−4−5−3−4−3
Depreciation & amortization000000000000
EBIT−2−2−2−2−2−3−3−4−5−3−4−3